{
    "info": [
      {
        "protocol_no": "03",
        "NCT": "NCT03785249",
        "jit": "Caris",
        "trial_name": "Mirati KRAS G12C"
      }
    ],
    "disease": [
      {
        "summary": "Advanced solid",
        "occurence": "",
        "details": [
          {
            "code": "Solid",
            "selection": "include"
          }
        ]
      }
    ],
    "query": [
      {
        "nct": "NCT03785249",
        "title": "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
        "current_status": "Recruiting",
        "status_verif_date": "March 2021",
        "last_update_date": "March 8, 2021",
        "trial_hold_status": "",
        "sponsor": "Mirati Therapeutics Inc.",
        "brief_summary": "This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.",
        "conditiions": "Advanced Cancer | Metastatic Cancer | Malignant Neoplastic Disease",
        "type": "Interventional",
        "phase": "Phase 1 | Phase 2",
        "arm": [
          {
            "cohortlabel": "Phase 1 Dose Exploration",
            "drug": "MRTX849 | NA",
            "arm_type": "Experimental",
            "line_of_therapy": "",
            "arm_hold_status": "",
            "biomarker": [
                {
                  "summary": "KRAS G12C mut",
                  "gene": "KRAS",
                  "type": "mutation",
                  "variant": "G12C",
                  "function": "",
                  "selection": "include"
                }
              ]
          },
          {
            "cohortlabel": "Phase 1b Expansion",
            "drug": "MRTX849 | NA",
            "arm_type": "Experimental",
            "line_of_therapy": "",
            "arm_hold_status": "",
            "biomarker": [
                {
                  "summary": "KRAS G12C mut",
                  "gene": "KRAS",
                  "type": "mutation",
                  "variant": "G12C",
                  "function": "",
                  "selection": "include"
                }
              ]
          },
          {
            "cohortlabel": "Phase 2",
            "drug": "MRTX849 | NA",
            "arm_type": "Experimental",
            "line_of_therapy": "",
            "arm_hold_status": "",
            "biomarker": [
                {
                  "summary": "KRAS G12C mut",
                  "gene": "KRAS",
                  "type": "mutation",
                  "variant": "G12C",
                  "function": "",
                  "selection": "include"
                }
              ]
          },
          {
            "cohortlabel": "Pilot Phase 1b Combination with Pembrolizumab",
            "drug": "MRTX849 | Pembrolizumab",
            "arm_type": "Experimental",
            "line_of_therapy": "",
            "arm_hold_status": "",
            "biomarker": [
                {
                  "summary": "KRAS G12C mut",
                  "gene": "KRAS",
                  "type": "mutation",
                  "variant": "G12C",
                  "function": "",
                  "selection": "include"
                }
              ]
          },
          {
            "cohortlabel": "Pilot Phase 1b Combination with Cetuximab",
            "drug": "MRTX849 | Cetuximab",
            "arm_type": "Experimental",
            "line_of_therapy": "",
            "arm_hold_status": "",
            "biomarker": [
                {
                  "summary": "KRAS G12C mut",
                  "gene": "KRAS",
                  "type": "mutation",
                  "variant": "G12C",
                  "function": "",
                  "selection": "include"
                }
              ]
          },
          {
            "cohortlabel": "Pilot Phase 1b Combination with Afatinib",
            "drug": "MRTX849 | Afatinib",
            "arm_type": "Experimental",
            "line_of_therapy": "",
            "arm_hold_status": "",
            "biomarker": [
                {
                  "summary": "KRAS G12C mut",
                  "gene": "KRAS",
                  "type": "mutation",
                  "variant": "G12C",
                  "function": "",
                  "selection": "include"
                }
              ]
          }
        ],
        "docs": "",
        "min_age": "18 Years",
        "criteria": "Inclusion Criteria:\n\nHistologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation\nUnresectable or metastatic disease\nStandard treatment is not available or patient declines\nAdequate organ function\n\nExclusion Criteria:\n\nHistory of intestinal disease or major gastric surgery or inability to swallow oral medications\nOther active cancer",
        "gender": "All",
        "link": "<a href=\"https://clinicaltrials.gov/ct2/show/NCT03785249\" target=\"_blank\">NCT03785249<\/a>"
      }
    ]
  }
  